# IWG 2023 response criteria for higher-risk MDS

Source: https://onco.cc/terms/iwg-2023-mds-response/  
OnCo record `iwg-2023-mds-response` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The IWG 2023 criteria define complete remission and other responses in higher-risk myelodysplastic syndromes, revised so that trial results track outcomes that matter to patients.

## Summary

The International Working Group response criteria for MDS from 2000 were revised in 2006 and 2018 (the latter for lower-risk disease). For higher-risk MDS, 36 experts using a modified Delphi process (Zeidan and colleagues, Blood 2023) changed the haemoglobin threshold for complete remission, added complete remission with limited count recovery and with partial haematological recovery as provisional categories, eliminated marrow complete remission, and standardised time-to-event endpoints and how responses are derived and reported.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: IWG 2023; IWG 2023 MDS response criteria; IWG 2006 MDS response criteria; CR with limited count recovery; CR with partial hematologic recovery

## Sources

- Zeidan et al., Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes (Blood 2023): https://doi.org/10.1182/blood.2022018604

## Connected records

- terms: [Complete response (CR) and partial response (PR)](https://onco.cc/terms/complete-response-term/), [MDS/MPN international response criteria (2015)](https://onco.cc/terms/mds-mpn-response/)
- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)

---
JSON: https://onco.cc/api/v1/entities/iwg-2023-mds-response.json